abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastická činidla - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastická činidla - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - mnohočetný myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
tecvayli
janssen-cilag international n.v. - teclistamab - mnohočetný myelom - antineoplastická činidla - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
arupsan 200mg tableta
accord healthcare polska sp. z o.o., varšava array - 18496 eslikarbazepin-acetÁt - tableta - 200mg - eslikarbazepin
arupsan 800mg tableta
accord healthcare polska sp. z o.o., varšava array - 18496 eslikarbazepin-acetÁt - tableta - 800mg - eslikarbazepin
eslikarbazepin neuraxpharm 800mg tableta
neuraxpharm bohemia s.r.o., praha array - 18496 eslikarbazepin-acetÁt - tableta - 800mg - eslikarbazepin
lamictal 100mg tableta
glaxosmithkline (ireland) limited, dublin array - 9440 lamotrigin - tableta - 100mg - lamotrigin
lamictal 25mg tableta
glaxosmithkline (ireland) limited, dublin array - 9440 lamotrigin - tableta - 25mg - lamotrigin
lamictal 5mg Žvýkací/dispergovatelná tableta
glaxosmithkline (ireland) limited, dublin array - 9440 lamotrigin - Žvýkací/dispergovatelná tableta - 5mg - lamotrigin